Evan Feinberg is the Founder and CEO of Genesis Therapeutics. During his graduate training with Vijay Pande at Stanford University, Dr. Feinberg co-invented several novel deep neural network architectures — including PotentialNet — which formed the basis for the Genesis Therapeutics AI platform. While in graduate school, Evan consulted on deep learning for Merck Research Laboratories. Motivated by the step-change improvement in molecular property prediction conferred by their methods, Feinberg founded Genesis to collaborate with big pharma and biotech alike on their small molecule drug discovery pipelines.

Evan received his Ph.D. in Biophysics at Stanford and his B.S. magna cum laude in Applied Physics at Yale.